

6 September 2022

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Change of Registered Office**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease announces that it has changed its registered office address.

The new registered office address for Scancell is:

Bellhouse Building  
Sanders Road  
Oxford Science Park  
Oxford OX4 4GD

**For further information, please contact:**

**Scancell Holdings plc** +44 (0) 20 3727 1000  
Dr John Chiplin, Executive Chairman  
Professor Lindy Durrant, CEO

**Panmure Gordon (UK) Limited** (Nominated Adviser and Joint Broker) +44 (0) 20 7886 2500  
Freddy Crossley/Emma Earl (Corporate Finance)  
Rupert Dearden (Corporate Broking)

**Stifel Nicolaus Europe Limited** (Joint Broker) +44 (0) 20 7710 7600  
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare  
Investment Banking)  
Nick Adams/Nick Harland (Corporate Broking)

**FTI Consulting** +44 (0) 20 3727 1000  
Simon Conway/Rob Winder/Alex Davis

**About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope<sup>®</sup> and ImmunoBody<sup>®</sup> for vaccines and GlyMab<sup>®</sup> and AvidiMab<sup>®</sup> for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope<sup>®</sup> and ImmunoBody<sup>®</sup>) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab<sup>™</sup>) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab<sup>®</sup>).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>